JP7016544B2 - アプタマーを用いた生体分子の映像化方法 - Google Patents
アプタマーを用いた生体分子の映像化方法 Download PDFInfo
- Publication number
- JP7016544B2 JP7016544B2 JP2019557747A JP2019557747A JP7016544B2 JP 7016544 B2 JP7016544 B2 JP 7016544B2 JP 2019557747 A JP2019557747 A JP 2019557747A JP 2019557747 A JP2019557747 A JP 2019557747A JP 7016544 B2 JP7016544 B2 JP 7016544B2
- Authority
- JP
- Japan
- Prior art keywords
- aptamer
- odn
- codn
- labeled
- erbb2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091023037 Aptamer Proteins 0.000 title claims description 168
- 238000003384 imaging method Methods 0.000 title claims description 10
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 155
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 153
- 206010028980 Neoplasm Diseases 0.000 claims description 58
- 201000011510 cancer Diseases 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 25
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 16
- 239000002202 Polyethylene glycol Substances 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- 230000000295 complement effect Effects 0.000 claims description 13
- 239000000523 sample Substances 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 11
- 238000012800 visualization Methods 0.000 claims description 11
- 239000007850 fluorescent dye Substances 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 235000012000 cholesterol Nutrition 0.000 claims description 8
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 92
- 238000012636 positron electron tomography Methods 0.000 description 31
- 238000003786 synthesis reaction Methods 0.000 description 23
- 206010006187 Breast cancer Diseases 0.000 description 22
- 208000026310 Breast neoplasm Diseases 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 20
- 238000001727 in vivo Methods 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 238000009396 hybridization Methods 0.000 description 13
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 7
- 238000001308 synthesis method Methods 0.000 description 7
- 239000011543 agarose gel Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000002194 synthesizing effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000002595 magnetic resonance imaging Methods 0.000 description 5
- 239000012217 radiopharmaceutical Substances 0.000 description 5
- 229940121896 radiopharmaceutical Drugs 0.000 description 5
- 230000002799 radiopharmaceutical effect Effects 0.000 description 5
- 108091008102 DNA aptamers Proteins 0.000 description 4
- 108091008103 RNA aptamers Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000009206 nuclear medicine Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- LSSQMISUDUUZCC-DWSYCVKZSA-N (2,5-dioxopyrrolidin-1-yl) 4-fluoranylbenzoate Chemical compound C1=CC([18F])=CC=C1C(=O)ON1C(=O)CCC1=O LSSQMISUDUUZCC-DWSYCVKZSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000012879 PET imaging Methods 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 102000007000 Tenascin Human genes 0.000 description 3
- 108010008125 Tenascin Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 2
- OLXZPDWKRNYJJZ-UHFFFAOYSA-N 5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(CO)O1 OLXZPDWKRNYJJZ-UHFFFAOYSA-N 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-BJUDXGSMSA-N ac1l2y5h Chemical compound [18FH] KRHYYFGTRYWZRS-BJUDXGSMSA-N 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000003320 cell separation method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 238000009126 molecular therapy Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- AVBGNFCMKJOFIN-UHFFFAOYSA-N triethylammonium acetate Chemical compound CC(O)=O.CCN(CC)CC AVBGNFCMKJOFIN-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- YKBGVTZYEHREMT-UHFFFAOYSA-N 2'-deoxyguanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(CO)O1 YKBGVTZYEHREMT-UHFFFAOYSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101000798762 Anguilla anguilla Troponin C, skeletal muscle Proteins 0.000 description 1
- 241000750690 Aptus Species 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 101000666340 Homo sapiens Tenascin Proteins 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102100021010 Nucleolin Human genes 0.000 description 1
- UUDHOSZAWIHGTB-UKKPGEIXSA-N OC[C@H](C(C1)O)O[C@H]1N(C=C(C(NCc1cccc2c1cccc2)=O)C(N1)=O)C1=O Chemical compound OC[C@H](C(C1)O)O[C@H]1N(C=C(C(NCc1cccc2c1cccc2)=O)C(N1)=O)C1=O UUDHOSZAWIHGTB-UKKPGEIXSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 102100038126 Tenascin Human genes 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- VVBXXVAFSPEIJQ-CVIPOMFBSA-N [(2r)-3-[[(2r)-1-[[(2s,5r,8r,11r,12s,15s,18s,21s)-15-[3-(diaminomethylideneamino)propyl]-21-hydroxy-5-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-2-(2-methylpropyl)-3,6,9,13,16,22-hexaoxo-8-propan-2-yl-10-oxa-1,4,7,14,17-pentazabicyclo[16.3.1]docosan-12-yl]am Chemical compound C([C@@H]1C(=O)N[C@@H](C(=O)O[C@H](C)[C@@H](C(N[C@@H](CCCN=C(N)N)C(=O)N[C@H]2CC[C@H](O)N(C2=O)[C@@H](CC(C)C)C(=O)N1C)=O)NC(=O)[C@H](NC(=O)[C@H](O)COS(O)(=O)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 VVBXXVAFSPEIJQ-CVIPOMFBSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 150000001345 alkine derivatives Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- KRHYYFGTRYWZRS-BJUDXGSMSA-M fluorine-18(1-) Chemical compound [18F-] KRHYYFGTRYWZRS-BJUDXGSMSA-M 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- AMWRITDGCCNYAT-UHFFFAOYSA-L manganese oxide Inorganic materials [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108010044762 nucleolin Proteins 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960003407 pegaptanib Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229960003766 thrombin (human) Drugs 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/534—Production of labelled immunochemicals with radioactive label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Optics & Photonics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
HER2が発現しているヒト乳癌細胞株であるBT474、KPL4、N87およびSK-BR-3を試験管および生体内試験に用いた。そして対照群として、他のヒト乳癌細胞株MDA-MB231をもって実験を行った。すべての細胞株は、ATCCから購入したものであり、10%FBSを含有するMEM培地に培養して維持した。
細胞内タンパク質を抽出するために、タンパク質分解酵素阻害剤が含まれた細胞溶解液を氷上で30分間培養した。このようにして得られた細胞溶解液を4℃、20分間遠心分離して精製した。タンパク質定量のためにブラッドフォード(Bradford)法を用いて定量化し、それぞれのサンプルから30μgのタンパク質抽出物を10%SDS-PAGEで電気泳動して分離した。その後、ニトロセルロース膜に移してHER2抗体と対照群であるβ-アクチン(beta-actin)抗体をプローブとして用いて、ECLでx線(x-ray)フィルムに感光した。
HER2-(+)標的ERBB2アプタマーの塩基配列は、下記表2に示す。
5’-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]-CAG CCA CAC CAC CAG-3’{[AP001-24]-ODN}を次のようにして合成した。
5’-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACA A]-CAG CCA CAC CAC CAG-3’{[AP001-25]-ODN}を、前述した{[AP001-24]-ODN}の合成方法により合成した。
5’-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]-CAG CCA CAC CAC CAG-idT-3’{[AP001-24]-ODN-idT}を、idT(逆位dT(invert dT))CPG(Glen、20-0302-10)を用いて、前述した{[AP001-24]-ODN}の合成方法により合成した。
5’-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACA A]-CAG CCA CAC CAC CAG-idT-3’{[AP001-25]-ODN-idT}を、idT CPG(Glen、20-0302-10)を用いて、前述した{[AP001-24]-ODN}の合成方法により合成した。
5’-コレステリル-[6CC 6GG CA6 G66 CGA 6GG AGG CC666G A66 ACA GCC CAG A]-CAG CCA CAC CAC CAG-3 ’{コレステリル-[AP001-24]-ODN}を、コレステロール-PA(Glen、10-1976-90)を用いて、前述した{[AP001-24]-ODN}の合成方法により合成した。
5’-コレステリル-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACA A]-CAG CCA CAC CAC CAG-3’{コレステリル-[AP001-25]-ODN}を、コレステロール-PA(Glen、10-1976-90)を用いて、前述した{[AP001-24]-ODN}の合成方法により合成した。
5’-コレステリル-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]-CAG CCA CAC CAC CAG-idT-3’{コレステリル-[AP001-24]-ODN-idT}を、idT CPG(Glen、20-0302-10)およびコレステロール-PA(Glen、10-1976-90)を用いて、前述した{[AP001-24]-ODN}の合成方法により合成した。
5’-コレステリル-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACA A]-CAG CCA CAC CAC CAG-idT-3’{コレステリル-[AP001-25]-ODN-idT}を、idT CPG(Glen、20-0302-10)およびコレステロール-PA(Glen、10-1976-90)を用いて、前述した{[AP001-24]-ODN}の合成方法により合成した。
5’-ペグ化(PEGylated)-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]-CAG CCA CAC CAC CAG-3’{ペグ化(PEGylated)-[AP001-24]-ODN}を、Polyethyleneglycol 2000 CED PA(ChemGenes、CLP-2119)を用いて、前述した{[AP001-24]-ODN}の合成方法により合成した。
5’-ペグ化(PEGylated)-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACA A]-CAG CCA CAC CAC CAG-3’{ペグ化(PEGylated)-[AP001-25]-ODN}を、ポリエチレングリコール(Polyethyleneglycol)2000 CED PA(ChemGenes、CLP-2119)を用いて、前述した{[AP001-24]-ODN}の合成方法により合成した。
5’-ペグ化(PEGylated)-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]-CAG CCA CAC CAC CAG-idT-3’{ペグ化(PEGylated)-[AP001-24]-ODN-idT}を、idT CPG(Glen、20-0302-10)およびポリエチレングリコール(Polyethyleneglycol)2000 CED PA(ChemGenes、CLP-2119)を用いて、前述した{[AP001-24]-ODN}の合成方法により合成した。
5’-ペグ化(PEGylated)-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACA A]-CAG CCA CAC CAC CAG-3’{ペグ化(PEGylated)-[AP001-25]-ODN-idT}を、idT CPG(Glen、20-0302-10)およびポリエチレングリコール(Polyethyleneglycol)2000 CED PA(ChemGenes、CLP-2119)を用いて、前述した{[AP001-24]-ODN}の合成方法により合成した。
下記図は、cODN-Cy5およびcODN-L-F18(L=リンカー(linker))の構造および合成を示す。
下記表3に、R-[ERBB2アプタマー]-ODN-X(R=H、コレステロール、またはPEG、X=H、またはidT)とcODN-Cy5とのハイブリダイゼーション(hybridization)構造をR-[ERBB2アプタマー]-X-hy(bp)-Cy5で示す。
18F-標識(labeled)cODNの合成は、既に報告されている過程(参考文献24)を中心にした。担体無添加(No-carrier-added)18F-フッ化物イオン(fluoride ion)を合成機(Tracerlab FXFN、GE Healthcare、Milwaukee、WI、USA)を用いて生成した後、メシレート(mesylate)と反応(100℃、10分間)した後、18F-フルオロ(fluoro)-PEG-アジド(azide)(18F-FPA)をHPLCを用いて精製した。5’-ヘキシニル相補オリゴヌクレオチド(5’-hexynyl complementary oligonucleotide)(5’-hex-cODN 200mg)にアセトニトリル(10mL)中の1M N,N-ジイソプロピルエチルアミン、アセトニトリル(20mL)中の100mMヨウ化銅(I)を入れ、18F-FPA(750e1100 MBq)を入れてクリックケミストリー(click chemistry)反応を行った(70℃、20分間)。合成された18F-標識(labeled)cODN(cODN-L-F18)は、HPLC H(Xbridge OST C18、10×50mm、溶離液アセトニトリル/0.1M TEAA5:95~95:5 20分かけて流速:5mL/分、UV(254nm))を用いて精製した。
下記表4にR-[ERBB2アプタマー(aptamer)]-ODN-X(R=H、コレステロール、またはPEG、X=OH、またはidT)とcODN-L-F18(L=リンカー(linker))とのハイブリダイゼーション(hybridization)構造をR-[ERBB2アプタマー(aptamer)]-X-hy(bp)-L-F18で示す。
BT474、KPL4、N87、SK-BR-3、およびMDA-MB231細胞株をカバーガラス(coverslip)に分注して一晩培養した。約80%程度が成長したとき、注意深く洗浄し、蛍光が標識されたERBB2アプタマー{R-[ERBB2アプタマー]-hy(bp)-Cy5}を250nMの濃度で処理して培養した。培養後、注意深く洗浄し、DAPIを含有する培養液をスライドに取り付けた。LSM700共焦点顕微鏡で蛍光を観察した。顕微鏡のセッティングは、FITC観察には488nmレーザーを、励起(excitation)、放出(emission)にはBP490-555を、そしてテキサスレッド(Texas red)では639nmレーザーを、放出にはLP640フィルタを用いた。
ERBB2アプタマーの特異度を流動細胞計測システム(BD Biosciences)を用いて、蛍光活性細胞分離法で検証した。BT474、KPL4、N87、SK-BR-3、またはMDA-MB231癌細胞株をペトリ皿に適正数継代培養し、80%程度まで成長するように培養した。細胞にトリプシンを処理し、PBSで洗浄した後、蛍光が標識されたODNを温度による相補的塩基でERBB2アプタマーに結合した。結合が完了した試料を細胞に処理した。ERBB2アプタマー{R-[ERBb2アプタマー]-hy(bp)-Cy5}と対照群として1%FBSを含有する抗体をそれぞれ4℃で30分間処理した。処理が完了した試料を洗浄した後、結合したERBB2アプタマーを測定し、蛍光活性細胞分離法により分析した。結果は、図6に示す。
4週齢Balb/cヌードマウスの皮下に17ββ-エストラジオール(estradiol)ペレットを首の側面部位に、癌が発生するほどの量でエストロゲンが放出するように移植した。数日後、1匹マウス当たり7×106程度の数でBT474またはKPL4ヒト乳癌細胞株を皮下に移植した。癌が3週間発生するようにした後、癌の成長をカリパス(caliper)で測定した。
マウスにF18放射性同位元素標識ERBB2アプタマーを注射して60分後から10分間の静的映像をInveon micro PET(Siemens、Knoxville、TN、USA)スキャナを用いて取得した。F18放射性同位元素標識ERBB2アプタマーの注射は、2%イソフルラン(Isoflurane)で呼吸麻酔した後、マウスの尾静脈に7.4MBqのF18放射性同位元素標識ERBB2アプタマーを注射した。取得されたリストモード(listmode)データは、サイノグラムに変換後、3Dサブセット化による期待値最大化(Ordered Subset Expectation Maximization(OSEM))アルゴリズムで再構成し、ASIpro(Concorde Microsystems Inc、Knoxville、TN)を用いて分析した。
HER2発現の証明と標的癌細胞に対するアプタマーの親和度
乳がん細胞株であるBT474の発現を調べるために、ウェスタンブロットと流動細胞計測法を行った。ウェスタンブロット分析により、遺伝子増幅に起因してHER2が過剰発現することが知られているSKBR3細胞株だけでなく、BT474における過剰発現を確認した。陰性対照群細胞株であるMDA-MB231では、該当する位置で信号が示されないことを確認した(図14)。
ERBB2アプタマーの細胞結合を、共焦点顕微鏡でさらに評価した(図16)。BT474 HER2陽性乳がん細胞株にアプタマーを処理した。ERbB2アプタマーは、蛍光で標識されて細胞表面で蛍光が観測され、このような細胞の表面にHER2構造体があることが確認された。細胞膜に沿ってアプタマーが示す蛍光が観測され、陰性対照群であるMDA-MB231細胞株では、いずれの蛍光シグナルも観測されなかったので、HER2が存在しないものと見られる。したがって、このERBB2アプタマーは、HER2陽性乳がん細胞株に結合することができ、HER2陰性細胞には、最小結合することが観察された。蛍光標識ODNと相補的塩基対をなしているERBB2アプタマー{[AP001-24]および[AP001-25]}を前述の実験と同様な方法により、乳がん細胞株であるKPL4、N87、SK-BR-3に処理した後、共焦点顕微鏡で蛍光を観察した。2種のERBB2アプタマーの両方とも、乳癌細胞株によく結合することが確認された。[AP001-24]は、細胞膜に沿って細胞表面で蛍光が観測され、[AP001-25]は、細胞内部でも蛍光が観測された。
動物micro PETを用いて、BT474またはKPL4癌のあるマウスの生体内分子の画像を時間別に得た。図17によると、18F標識HER2特異ERBB2アプタマーが、マウスの左脇に存在する癌組織に摂取が非常に増加することが観察された。120分間得られた映像では、がんは、水平面と冠状面の映像においてERBB2アプタマーによって明らかに標識された。腸と膀胱での生理的な摂取が明らかに示されたことから、放射線医薬品の二つの主な排出経路を反映する。
1. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990;249:505-10.
2. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990;346:818-22.
3. Stoltenburg R, Reinemann C, Strehlitz B. SELEX--a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomolecular engineering. 2007;24:381-403
4. Spiridonova VA, Kopylov AM. DNA aptamers as radically new recognition elements for biosensors. Biochemistry Biokhimiia. 2002;67:706-9.
5. Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clinical chemistry. 1999;45:1628-50.
6. Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature. 1992;355(6360):564-6.
7. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Experimental and molecular pathology. 2009;86:151-64.
8. Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer research. 2002;62:4029-33.
9. Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:15416-21.
10. James W. Aptamers in the virologists' toolkit. The Journal of general virology. 2007;88(Pt 2):351-64.
11. Doggrell SA. Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration. Expert opinion on pharmacotherapy. 2005;6:1421-3.
12. Dausse E, Da Rocha Gomes S, Toulme JJ. aptamers: a new class of oligonucleotides in the drug discovery pipeline? Current opinion in pharmacology. 2009;9:602-7.
13. Mitri Z, Constantine T, O'Regan R. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemotherapy research and practice. 2012;2012:743193.
14. Burstein HJ. The distinctive nature of HER2-positive breast cancers. The New England journal of medicine. 2005;353:1652-4.
15. Tan M, Yu D. Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Advances in experimental medicine and biology. 2007;608:119-29.
16. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature reviews Cancer. 2009;9:463-75.
17. Dastjerdi K, Tabar GH, Dehghani H, Haghparast A. Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX. Biotechnology and applied biochemistry. 2011;58:226-30.
18. Liu Z, Duan JH, Song YM, Ma J, Wang FD, Lu X et al. Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. Journal of translational medicine. 2012;10:148.
19. Mahlknecht G, Maron R, Mancini M, Schechter B, Sela M, Yarden Y. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proceedings of the National Academy of Sciences of the United States of America. 2013;110:8170-5.
20. Mahlknecht G, Sela M, Yarden Y. Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy. Methods in molecular biology (Clifton, NJ). 2015;1317:3-15.
21. Moosavian SA, Jaafari MR, Taghdisi SM, Mosaffa F, Badiee A, Abnous K. Development of RNA aptamers as molecular probes for HER2(+) breast cancer study using cell-SELEX. Iranian journal of basic medical sciences. 2015;18:576-86.
22. James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiological reviews. 2012;92:897-965.
23. Hicke BJ, Stephens AW, Gould T, Chang YF, Lynott CK, Heil J et al. Tumor targeting by an aptamer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2006;47:668-78.
24. Jacobson O, Yan X, Niu G, Weiss ID, Ma Y, Szajek LP et al. PET imaging of tenascin-C with a radiolabeled single-stranded DNA aptamer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2015;56:616-21.
25. Pala K, Serwotka A, Jelen F, Jakimowicz P, Otlewski J. Tumor-specific hyperthermia with aptamer-tagged superparamagnetic nanoparticles. International journal of nanomedicine. 2014;9:67-76. and Lee JH, Chae YC, Kim Y, Kang H, Im JH, Kim JI, Kim KS, Jang SK, Oh IU, Choi MJ, Kang WJ. "
which selectively binds to ERBB2 receptor and uses thereof" US 2015/0005368 A1 (Jan. 1, 2015)
26. Flagothier J, Kaisin G, Mercier F, Thonon D, Teller N, Wouters J et al. Synthesis of two new alkyne-bearing linkers used for the preparation of siRNA for labeling by click chemistry with fluorine-18. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine. 2012;70:1549-57.
27. Ramenda T, Steinbach J, Wuest F. 4-[18F]Fluoro-N-methyl-N-(propyl-2-yn-1-yl)benzenesulfonamide ([18F]F-SA): a versatile building block for labeling of peptides, proteins and oligonucleotides with fluorine-18 via Cu(I)-mediated click chemistry. Amino acids. 2013;44:1167-80.
28. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic acids research. 2003;31(13):3406-15.
29. Kibbe WA. OligoCalc: an online oligonucleotide properties calculator. Nucleic acids research. 2007;35(Web Server issue):W43-6.
30. Tang G, Zeng W, Yu M, Kabalka G. Facile synthesis of N-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB) for protein labeling. Journal of Labelled Compounds and Radiopharmaceuticals. 2008;51:68-71.
31. Tang G, Tang X, Wang X. A facile automated synthesis of N-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB) for 18F-labeled cell-penetrating peptide as PET tracer. Journal of Labelled Compounds and Radiopharmaceuticals. 2010;53:543-7.
32. Scott PJH, Shao X. Fully automated, high yielding production of N-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB), and its use in microwave-enhanced radiochemical coupling reactions. Journal of Labelled Compounds and Radiopharmaceuticals. 2010;53:586-91.
33. Kraus MH, Popescu NC, Amsbaugh SC, King CR. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. The EMBO journal. 1987;6:605-10.
34. Varmira K, Hosseinimehr SJ, Noaparast Z, Abedi SM. An improved radiolabelled RNA aptamer molecule for HER2 imaging in cancers. Journal of drug targeting. 2014;22:116-22.
35. Bouchard PR, Hutabarat RM, Thompson KM. Discovery and development of therapeutic aptamers. Annual review of pharmacology and toxicology. 2010;50:237-57.
36. Sun H, Zhu X, Lu PY, Rosato RR, Tan W, Zu Y. Oligonucleotide aptamers: new tools for targeted cancer therapy. Molecular therapy Nucleic acids. 2014;3:e182.
37. Lao YH, Phua KK, Leong KW. aptamer nanomedicine for cancer therapeutics: barriers and potential for translation. ACS nano. 2015;9:2235-54.
38. Sun H, Zu Y. A Highlight of Recent Advances in Aptamer Technology and Its Application. Molecules. 2015;20:11959-80.
39. Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN, Jr., Harzstark AL et al. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Investigational new drugs. 2014;32:178-87.
40. Dassie JP, Hernandez LI, Thomas GS, Long ME, Rockey WM, Howell CA et al. Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen. Molecular therapy : the journal of the American Society of Gene Therapy. 2014;22:1910-22.
41. Xu W, Siddiqui IA, Nihal M, Pilla S, Rosenthal K, Mukhtar H et al. Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer. Biomaterials. 2013;34:5244-53.
42. Lim EK, Kim B, Choi Y, Ro Y, Cho EJ, Lee JH et al. Aptamer-conjugated magnetic nanoparticles enable efficient targeted detection of integrin alphavbeta3 via magnetic resonance imaging. Journal of biomedical materials research Part A. 2014;102:49-59.
43. Hu H, Dai A, Sun J, Li X, Gao F, Wu L et al. Aptamer-conjugated Mn3O4@SiO2 core-shell nanoprobes for targeted magnetic resonance imaging. Nanoscale. 2013;5:10447-54.
Claims (7)
- 下記化学式1のアプタマー及び化学式2の標識cODNが混成化された標識アプタマーを含む腫瘍性疾患部位の映像化用組成物。
[化学式1]
R-[ERBB2アプタマー]-ODN(オリゴデオキシヌクレオチド)-X
〔式中、Rは、H、コレステロール、またはPEG(ポリエチレングリコール)であり、
ERBB2アプタマーは、次の配列番号35または配列番号36の塩基配列を含み、
ODNは、配列番号38の配列を含むオリゴデオキシヌクレオチドであり、
Xは、H、idT(逆位デオキシチミジン(inverted deoxythymidine))、LNA(ロックド核酸(Locked Nucleic Acid))、2’-メトキシヌクレオチド、2’-アミノヌクレオチド、または2’F-ヌクレオチドである。〕
[化学式2]
cODN-Y
〔式中、cODNは、前記ODNに相補的な配列のオリゴデオキシヌクレオチドであり、
Yは、蛍光染料またはリンカー-放射性同位元素である。〕 - 前記同位元素は、18F、32P、123I、89Zr、67Ga、201Tl、111In-111から選択されることを特徴とする請求項1に記載の映像化用組成物。
- 前記同位元素は、18Fであることを特徴とする請求項2に記載の映像化用組成物。
- 前記蛍光染料は、シアニン蛍光染料であることを特徴とする請求項1に記載の映像化用組成物。
- 前記蛍光染料は、Cy5であることを特徴とする請求項4に記載の映像化用組成物。
- 患者から分離された生物学的試料に請求項1ないし請求項5のいずれか一項に記載の映像化用組成物を処理するステップと、
前記試料におけるアプタマーの結合程度を測定するステップと、
前記試料におけるアプタマーの結合程度と、正常な試料におけるアプタマーの結合程度を比較するステップであって、前記試料におけるアプタマーの結合度合が、前記正常な試料よりも高い場合には、癌または癌転移の存在を検出する、ステップとを含む、生体外で癌または癌転移を検出する方法。 - 下記化学式2のcODNとYを反応させ、化学式2の標識cODNを製造し、それを精製して得るステップと、
前記標識cODNを下記化学式1のアプタマーと混成化して標識アプタマーを得るステップとを含む、請求項1ないし請求項5のいずれか一項に記載の腫瘍性疾患部位の映像化用組成物の製造方法。
[化学式1]
R-[ERBB2アプタマー]-ODN(オリゴデオキシヌクレオチド)-X
〔式中、Rは、H、コレステロール、またはPEGであり、
ERBB2アプタマーは、次の配列番号35または配列番号36の塩基配列を含み、
ODNは、配列番号38の配列を含むオリゴデオキシヌクレオチドであり、
Xは、H、idT(逆位デオキシチミジン(inverted deoxythymidine))、LNA(ロックド核酸(Locked Nucleic Acid))、2’-メトキシヌクレオチド、2’-アミノヌクレオチド、または2’F-ヌクレオチドである。〕
[化学式2]
cODN-Y
〔式中、cODNは、前記ODNに相補的な配列のオリゴデオキシヌクレオチドであり、
Yは、蛍光染料またはリンカー-放射性同位元素である。〕
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0053456 | 2017-04-26 | ||
KR20170053456 | 2017-04-26 | ||
KR10-2018-0046550 | 2018-04-23 | ||
KR1020180046550A KR102062115B1 (ko) | 2017-04-26 | 2018-04-23 | 압타머를 이용한 생체 분자 영상화 방법 |
PCT/KR2018/004770 WO2018199607A1 (ko) | 2017-04-26 | 2018-04-25 | 압타머를 이용한 생체 분자 영상화 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020517675A JP2020517675A (ja) | 2020-06-18 |
JP7016544B2 true JP7016544B2 (ja) | 2022-03-03 |
Family
ID=64329202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019557747A Active JP7016544B2 (ja) | 2017-04-26 | 2018-04-25 | アプタマーを用いた生体分子の映像化方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11499156B2 (ja) |
EP (1) | EP3636287A4 (ja) |
JP (1) | JP7016544B2 (ja) |
KR (1) | KR102062115B1 (ja) |
CN (1) | CN110621351B (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114703194B (zh) * | 2022-05-24 | 2022-09-02 | 中山大学附属第五医院 | 一种氟-18标记的cd63靶向化合物及其制备方法和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
KR101759209B1 (ko) * | 2010-01-22 | 2017-07-19 | 성균관대학교산학협력단 | Her-2 과발현 유방암 세포 또는 조직에 특이적으로 결합할 수 있는 핵산 압타머 및 그 용도 |
KR101279584B1 (ko) * | 2011-06-24 | 2013-06-28 | 대한민국 (식품의약품안전처장) | Erbb2 수용체에 선택적으로 결합하는 압타머 및 이의 용도 |
KR101405440B1 (ko) | 2012-07-31 | 2014-06-20 | 연세대학교 산학협력단 | 인테그린αvβ3에 특이적 압타머 및 이의 용도 |
KR101279585B1 (ko) * | 2013-01-09 | 2013-06-27 | 대한민국 (식품의약품안전처장) | Erbb2 수용체에 선택적으로 결합하는 압타머 및 이의 용도 |
KR102084472B1 (ko) | 2013-10-21 | 2020-03-04 | 연세대학교 산학협력단 | 다양한 압타머에 적용 가능한 방사성동위원소 표지된 핵산 구조체 개발 및 표지방법 |
-
2018
- 2018-04-23 KR KR1020180046550A patent/KR102062115B1/ko active IP Right Grant
- 2018-04-25 CN CN201880027916.2A patent/CN110621351B/zh active Active
- 2018-04-25 EP EP18791814.9A patent/EP3636287A4/en active Pending
- 2018-04-25 JP JP2019557747A patent/JP7016544B2/ja active Active
- 2018-04-25 US US16/608,645 patent/US11499156B2/en active Active
Non-Patent Citations (1)
Title |
---|
PARK, J.Y. et al.,Biomaterials,2016年,Vol. 100,pp. 143-51 |
Also Published As
Publication number | Publication date |
---|---|
KR102062115B1 (ko) | 2020-01-03 |
CN110621351A (zh) | 2019-12-27 |
CN110621351B (zh) | 2022-11-04 |
US20200157543A1 (en) | 2020-05-21 |
JP2020517675A (ja) | 2020-06-18 |
EP3636287A4 (en) | 2021-01-27 |
EP3636287A1 (en) | 2020-04-15 |
KR20180120092A (ko) | 2018-11-05 |
US11499156B2 (en) | 2022-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Limoni et al. | Engineered exosomes for targeted transfer of siRNA to HER2 positive breast cancer cells | |
Kim et al. | PET imaging of HER2 expression with an 18F-fluoride labeled aptamer | |
Zhu et al. | Combinatorial screening of DNA aptamers for molecular imaging of HER2 in cancer | |
Radom et al. | Aptamers: molecules of great potential | |
Cerchia et al. | Targeting cancer cells with nucleic acid aptamers | |
JP6797108B2 (ja) | タンパク質/オリゴヌクレオチドコアシェルナノ粒子治療薬 | |
Lin et al. | Rationally designed multivalent aptamers targeting cell surface for biomedical applications | |
Han et al. | Application and development of aptamer in cancer: from clinical diagnosis to cancer therapy | |
Hatanaka et al. | Development of double-stranded siRNA labeling method using positron emitter and its in vivo trafficking analyzed by positron emission tomography | |
US20100234450A1 (en) | Molecular targeting agents | |
López‐Colón et al. | Aptamers: turning the spotlight on cells | |
Song et al. | Advances in aptamer-based nuclear imaging | |
Park et al. | Hybridization-based aptamer labeling using complementary oligonucleotide platform for PET and optical imaging | |
Perkins et al. | Radiolabelled aptamers for tumour imaging and therapy | |
Wang et al. | Framework nucleic acids in nuclear medicine imaging: shedding light on nano–bio interactions | |
US20190209695A1 (en) | Pharmaceutical Compositions for High-Capacity Targeted Delivery | |
Croci et al. | 64Cu and fluorescein labeled anti-miRNA peptide nucleic acids for the detection of miRNA expression in living cells | |
JP7016544B2 (ja) | アプタマーを用いた生体分子の映像化方法 | |
Jia et al. | Activatable dual cancer-related RNA imaging and combined gene-chemotherapy through the target-induced intracellular disassembly of functionalized DNA tetrahedron | |
JP2024052931A (ja) | 細胞認識およびインテグレーションのための核酸 | |
Zhong et al. | Advances of aptamer-based clinical applications for the diagnosis and therapy of cancer | |
Park et al. | Enhancement of in vivo targeting properties of ErbB2 aptamer by chemical modification | |
Äärelä et al. | In Vivo Imaging of [60] Fullerene-Based Molecular Spherical Nucleic Acids by Positron Emission Tomography | |
oh Jung et al. | A new fluorescence/PET probe for targeting intracellular human telomerase reverse transcriptase (hTERT) using Tat peptide-conjugated IgM | |
Case et al. | Engineered charge redistribution of Gp2 proteins through guided diversity for improved PET imaging of epidermal growth factor receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191224 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191224 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201215 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210311 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210511 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210614 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210706 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211104 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20211104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20211105 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20211130 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20211207 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220104 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220119 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7016544 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |